Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole in Treatment-Resistant Schizophrenia
NCT06270108Phase 1Recruiting
- Sponsor
- King's College London
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of riluzole in schizophrenia (3 arms), sponsored by King's College London. Primary endpoint: Change in glutamate levels at Day 56. Started Nov 2022; status: recruiting.
02
Drugs
riluzole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06270108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06270108.